Natixis Advisors LLC Purchases 2,632 Shares of Cencora, Inc. $COR

Natixis Advisors LLC grew its position in Cencora, Inc. (NYSE:COR) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 164,229 shares of the company’s stock after acquiring an additional 2,632 shares during the quarter. Natixis Advisors LLC owned 0.08% of Cencora worth $51,326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of COR. Mirae Asset Global Investments Co. Ltd. lifted its position in Cencora by 13.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares during the last quarter. AustralianSuper Pty Ltd bought a new stake in shares of Cencora in the 3rd quarter worth about $26,191,000. Acadian Asset Management LLC increased its holdings in shares of Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after buying an additional 232,539 shares during the last quarter. Mediolanum International Funds Ltd raised its position in shares of Cencora by 133.0% during the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock valued at $17,342,000 after buying an additional 32,138 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its holdings in shares of Cencora by 40.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after acquiring an additional 4,973 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Evercore dropped their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. Barclays lifted their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Bank of America cut their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Finally, Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $399.00.

Cencora Stock Up 0.9%

Shares of NYSE COR opened at $361.80 on Tuesday. Cencora, Inc. has a 1 year low of $251.94 and a 1 year high of $377.54. The firm has a 50-day simple moving average of $354.60 and a two-hundred day simple moving average of $337.09. The company has a market cap of $70.38 billion, a P/E ratio of 43.49, a PEG ratio of 1.67 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the firm posted $3.73 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio is 28.85%.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,220 shares of company stock worth $5,282,867 over the last quarter. Company insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.